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AbstrACt
Objectives To evaluate the cost-effectiveness of routine 
use of cell salvage during caesarean section in mothers 
at risk of haemorrhage compared with current standard 
of care.
Design Model-based cost-effectiveness evaluation 
alongside a multicentre randomised controlled trial. Three 
main analyses were carried out on the trial data: (1) based 
on the intention-to-treat principle; (2) based on the per-
protocol principle; (3) only participants who underwent an 
emergency caesarean section.
setting 26 obstetric units in the UK.
Participants 3028 women at risk of haemorrhage 
recruited between June 2013 and April 2016.
Interventions Cell salvage (intervention) versus routine 
care without salvage (control).
Primary outcome measures Cost-effectiveness based 
on incremental cost per donor blood transfusion avoided.
results In the intention-to-treat analysis, the mean 
difference in total costs between cell salvage and 
standard care was £83. The estimated incremental cost-
effectiveness ratio (ICER) was £8110 per donor blood 
transfusion avoided. For the per-protocol analysis, the 
mean difference in total costs was £92 and the ICER was 
£8252. In the emergency caesarean section analysis, the 
mean difference in total costs was £55 and the ICER was 
£13 713 per donor blood transfusion avoided. This ICER 
is driven by the increased probability that these patients 
would require a higher level of postoperative care and 
additional surgeries. The results of these analyses were 
shown to be robust for the majority of deterministic 
sensitivity analyses.
Conclusions The results of the economic evaluation 
suggest that while routine cell salvage is a marginally 
more effective strategy than standard care in avoiding a 
donor blood transfusion, there is uncertainty in relation 
to whether it is a less or more costly strategy. The lack of 
long-term data on the health and quality of life of patients 
in both arms of the trial means that further research is 
needed to fully understand the cost implications of both 
strategies.
trial registration number ISRCTN66118656.
IntrODuCtIOn 
Excessive blood loss (haemorrhage) in child-
birth is a life-threatening condition which is 
an important cause of maternal death,1 emer-
gency hysterectomy2 and maternal critical 
care admission3 among women undergoing a 
caesarean section.4 The treatment for major 
haemorrhage includes donor blood trans-
fusion. However, red cell concentrates used 
in donor transfusion are a scarce, nationally 
pooled resource in demand simultaneously 
by many clinical services.5 Furthermore, 
such transfusions carry risks for recipients 
as a result of incompatibility or infection.6 
Consequently, there is a recognised need to 
make caesarean safer while at the same time 
strengths and limitations of this study
 ► Study strengths of this model-based economic 
evaluation include that it was based on a rigorously 
conducted randomised controlled trial (RCT) and it 
benefited from significant clinical and statistical in-
put throughout its design and development.
 ► The analyses were conducted from a healthcare 
perspective, and the cost and outcome data mea-
sures incorporated into the model were collected 
prospectively during the RCT using forms filled out 
during the preoperative, intraoperative and postop-
erative phases and at the time of discharge from 
hospital.
 ► A limitation of the study is that not all potential out-
comes have been included because of the limited 
time scale in the model and the lack of long-term 
data.
 ► A further limitation of the evaluation is that out-
comes were expressed in terms of clinical effec-
tiveness rather than in terms of a standard unit of 
benefit such as the quality-adjusted life year.
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promoting the use of transfusion alternatives harnessing 
the patient’s own reserves where feasible.7 8
Intraoperative cell salvage (IOCS), which collects, 
processes and returns the woman’s own blood lost during 
surgery, is increasingly being deployed during caesareans. 
It has been shown to reduce the need for donor blood 
transfusions in a wide spectrum of surgical disciplines.9 10
This study presents the results of a model-based 
economic evaluation which compared the relative cost 
and cost-effectiveness of routine cell salvage with standard 
transfusion with donor blood in caesarean section. This 
study is part a wider NIHR-HTA randomised controlled 
trial (RCT) exploring the effectiveness and cost-effective-
ness of the use of cell salvage compared with donor blood 
transfusion during caesarean section.11 Primary data 
on costs and resource use were collected prospectively 
alongside the trial and the principal outcome for the 
economic evaluation was the cost per donor blood trans-
fusion avoided.
MethODs
Full details of the RCT are reported elsewhere.11 Briefly, 
the study was performed in 26 obstetric units. The sample 
comprised women who were admitted to a participating 
labour ward and who fulfilled all of the following inclu-
sion criteria: aged >16 years; able to provide informed 
consent; undergoing delivery by caesarean section with 
an identifiable increased risk of haemorrhage, defined as 
all emergency caesarean sections, where maternal or fetal 
compromise is suspected, and elective caesarean section 
for all indications other than maternal request or breech 
Figure 1 Decision tree structure.
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presentation. Participating women were randomised 
to either caesarean section with cell salvage (interven-
tion group) or to caesarean section without cell salvage 
(control group) for which transfusion of donor blood was 
carried out according to local guidelines. The primary 
outcome for the RCT was the proportion of women 
receiving donor blood transfusion due to haemorrhage. 
For the economic analysis, a decision analytic model was 
deemed the most suitable method of presenting the alter-
native pathways and collating the data for analysis. The 
economic evaluation took the form of a cost-effectiveness 
analysis from the perspective of the healthcare provider 
based on the principal clinical outcome of the trial, that 
is, the proportion of women receiving donor blood trans-
fusion due to haemorrhage. Given the objectives of the 
trial and the duration of follow-up, outcomes beyond the 
trial endpoint were not considered plausible or relevant 
in the model-based analysis.
Model structure
A decision tree model was developed in TreeAge Pro 
2016 (TreeAge Software, Williamstown, Massachu-
setts, USA) to represent the alternative strategies. The 
pathways of the model (see figure 1) represent, as far 
as possible, the clinical procedures carried out in the 
study.
Clinical data used in the model
The model combines the probability of a woman 
following a particular path and the associated costs. Prob-
abilities, detailed in table 1, were obtained from the trial 
and attached to each pathway.
Resource use and costs
The resource use for both arms of the trial was estimated 
by evaluating the individual components of these proce-
dures (bottom-up costing). Unit cost data were then 
attached to the resource use. Data were collected on all 
major National Health Service (NHS) resource use for 
each patient using the trial case report forms.
For the analysis, intraoperative and postoperative 
resource use data were obtained from the SALVage in 
Obstetrics (SALVO) trial. The main resource use moni-
tored included: equipment and disposables required for 
the cell salvage procedure; additional staff called into 
theatre solely for the purposes of cell salvage; drugs used 
in the caesarean section procedure; length and type of 
hospital inpatient stay including any additional treatment 
required attributed to the caesarean procedure; the use 
of donor blood transfusion and salvaged blood transfu-
sion to deal with haemorrhage and its consequences.
Intraoperative costs were estimated for each item to 
arrive at a mean cost per caesarean procedure for each 
Table 1 Probabilities used in the model
Trial data Probability Distribution
Cell salvage intended
Cell salvage intended → allocated treatment received (machine is on) 1432/1498 0.96 Beta
Allocated treatment received → salvaged blood returned 726/1432 0.51 Beta
Allocated treatment received → salvaged blood not returned 703/1432 0.49 Beta
Salvaged blood returned → donor blood transfusion given 22/726 0.03 Beta
Salvaged blood returned → donor blood transfusion not given 704/726 0.97 Beta
Salvaged blood not returned → donor blood transfusion given 9/703 0.01 Beta
Salvaged blood not returned → donor blood transfusion not given 697/703 0.99 Beta
Cell salvage intended → allocated treatment not received (machine is off) 66/1498 0.04 Beta
Allocated treatment not received → donor blood transfusion given 6/66 0.09 Beta
Allocated treatment not received → donor blood transfusion not given 60/66 0.91 Beta
Standard care intended
Standard care intended → allocated treatment received (machine is off) 1434/1492 0.96 Beta
Allocated treatment received → donor blood transfusion given 47/1434 0.03 Beta
Allocated treatment received → donor blood transfusion not given 1387/1434 0.97 Beta
Standard care intended → allocated treatment not received (machine is on) 58/1492 0.04 Beta
Allocated treatment not received → salvaged blood returned 35/58 0.60 Beta
Allocated treatment not received → salvaged blood not returned 23/58 0.40 Beta
Salvaged blood returned → donor blood transfusion given 4/35 0.11 Beta
Salvaged blood returned → donor blood transfusion not given 31/35 0.89 Beta
Salvaged blood not returned → donor blood transfusion given 1/23 0.04 Beta
Salvaged blood not returned → donor blood transfusion not given 22/23 0.96 Beta
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treatment pathway in the model. To estimate the cost of a 
caesarean section procedure, some costs were calculated 
at the patient level, for example, swab washing, and some 
at the procedural level, for example, drugs used in the 
caesarean section procedure (see table 2). Postoperative 
costs were estimated for each item based on their occur-
rence in each brand of the model to arrive at a mean cost 
per patient for each branch (see table 3).
Analysis
Given the objectives of the trial and the duration of 
follow-up, a within-trial economic analysis was carried 
out. The analysis took the perspective of the NHS and 
Personal Social Services (PSS) following current recom-
mendations from National Institute of Health and Care 
Excellence (NICE).12 The main economic analysis was a 
cost-effectiveness analysis (CEA) with results expressed as 
cost per donor transfusion avoided.
We carried out three main analyses on the trial data. 
The first analysis was based on the intention-to-treat 
(ITT) principle (Analysis ITT). In this method, patients 
are compared within the treatment groups to which they 
were originally randomised irrespective of the treatment 
received.13 This method of analysis allows the estimates to 
follow real-life scenarios in which patients may not always 
receive the planned treatment. ITT is recommended to 
ensure that the benefits of a given intervention are not 
exaggerated.13 The second analysis was based on the 
treatment actually received by patients irrespective of 
randomisation (Analysis ‘per protocol’ (PP)). Within the 
SALVO trial, equal numbers of patients were randomised 
to either cell salvage or standard care. However, because 
some clinicians managing women in the control arm 
had access to a cell salvage machine, it was possible that 
women in the control arm could receive cell salvage in 
place of a donor blood transfusion. A PP analysis was 
carried out to look at the effect of treatment received 
on the outcome estimates. Therefore, in Analysis PP, all 
patients who received cell salvage were compared with 
those who received standard care, irrespective of the treat-
ment to which they were randomised. The third analysis 
considered only patients who underwent an emergency 
caesarean section (Analysis ECS). This analysis was consid-
ered necessary as the SALVO trial found that numerically, 
there was a greater reduction in the rate of transfusion 
within the emergency patient group compared with the 
elective patient group. This analysis followed the same 
methodology as the ITT and PP analyses. Deterministic 
and probabilistic sensitivity analyses (PSAs) were carried 
out for each analysis to explore the effects of the inherent 
uncertainty in parameter estimates on model results.
Patient and public involvement
The UK National Childbirth Trust collaborated in the 
project by providing patient and public input through 
involvement in trial design and protocol development. 
Prior to the SALVO trial, a survey was conducted among 
women who received cell salvage, showing that they 
perceived the interventions as reassuring, safe and prefer-
able to donor blood transfusion. A patient representative 
was a member of the trial steering committee to provide 
oversight and advice regarding recruitment, dissemina-
tion and general trial management. We are planning to 
disseminate findings to participants in the form of a news-
letter following primary publication of these results.
results
The results of the ITT analysis (Analysis ITT) suggest that 
routine cell salvage is more costly than standard care with 
the mean difference in total costs per patient estimated 
at £83. The incremental cost-effectiveness ratio (ICER) 
representing the additional cost of routine cell salvage 
during caesarean section in women at risk of haemor-
rhage compared with standard care for these women was 
estimated to be approximately £8110 per donor blood 
transfusion avoided. The overall result, based on the PP 
analysis (Analysis PP), was an ICER of £8252 per trans-
fusion avoided for cell salvage compared with standard 
care. The ECS (Analysis ECS) resulted in an ICER of 
£13 713 per transfusion avoided. See table 4.
The results of the corresponding PSAs are presented 
using cost-effectiveness acceptability curves (CEACs) 
to graphically represent uncertainty in the appropriate 
threshold cost-effectiveness value (figure 2). The CEAC 
for Analysis ITT shows that the probability that routine 
cell salvage is cost-effective increases as the willingness to 
pay for a donor blood transfusion avoided increases. If 
the maximum willingness to pay for a donor blood trans-
fusion avoided was £50 000, for example, the probability 
of routine cell salvage being cost-effective would be 62%. 
For Analysis PP, the probability that routine cell salvage 
was cost-effective at a willingness to pay £50 000 would 
be 63%. The CEAC for Analysis ECS shows that the prob-
ability that cell salvage is cost-effective remains between 
47% and 55% as the willingness to pay for a donor blood 
transfusion avoided increases.
Deterministic sensitivity analysis
A number of deterministic sensitivity analyses were 
conducted in each analysis (see table 5):
i. The main analyses used costs for consumables based 
on a particular model of the cell saver machine. To 
assess the difference that variation in these estimates 
would make, the unit costs were replaced with unit 
costs obtained from the NICE costing statement for 
blood transfusion.14 This had a marginal impact on 
the ICER in each analysis. The impact of the inclu-
sion of acquisition costs for a cell salvage machine 
was also explored and found this had only a minimal 
impact on the ICER in each analysis. In the trial, 202 
cases used a cell salvage machine that required con-
sumables for collection only, even where the blood 
was not processed. The impact of including costs 
for the consumables used by this machine, where 
the machine is only set up for processing in patients 
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having blood returned and where swab washing is not 
conducted, resulted in an ICER of £1022 in Analysis 
ITT, £1184 in Analysis PP. In Analysis ECS, there was 
a dominant result in that cell salvage was considered 
less costly and more effective compared with stan-
dard care.
ii. The base case analyses used the mean length of time 
additional staff were present in theatre in each arm 
solely for the purposes of cell salvage. In the sensitiv-
ity analysis, the cost of additional staff was removed. 
This reduced the ICER to £7065 in Analysis ITT, 
£7210 in Analysis PP and £10 932 in Analysis ECS.
iii. To facilitate robust evaluation in cost-effectiveness 
analyses relating to donor blood, a comprehensive 
estimate for the cost of a unit of donor blood is re-
quired. The NHS Blood and Transplant Authority 
have valued the cost of RBC to be £120 per unit based 
on direct costs to the healthcare services.15 However, 
there is significant uncertainty surrounding this 
figure. We conducted a study (submitted for publica-
tion) parallel to the SALVO trial that aimed to dissect 
the current price of blood. We explored what ele-
ments are contributing to the current cost of blood 
and what elements are missing. Our study concluded 
that the current costing approach of assuming there 
will always be an adequate supply of donor blood must 
be replaced with including provisions for the con-
tinued shrinking of the donor pool and the impact 
that future shocks to the blood supply system could 
have. This sensitivity analysis assessed the difference 
that variation in the estimated cost of blood made to 
the overall cost-effectiveness of routine cell salvage. 
Raising the cost of a three-unit transfusion of RBC to a 
hypothetical cost of £1500 reduced the ICER by £974 
in both the ITT and PP analysis and it reduced the 
ICER by over £1000 in the ECS. Threshold analysis 
showed that for routine cell salvage to be considered 
cost-effective, the cost of an RBC transfusion would 
have to increase to £8637 in Analysis ITT, £8778 in 
Analysis PP and £13 186 in Analysis ECS.
DIsCussIOn
Principal findings
The results of this economic evaluation suggest that 
routine cell salvage is more costly than standard care 
with the average cost per patient estimated at £1327. 
The ICER for this strategy compared with standard care 
is approximately £8110 per donor blood transfusion 
avoided. The PSA suggests that at an arbitrary willingness 
to pay threshold of £50 000, the probability of routine cell 
salvage being cost-effective is 62%.
The results of this analysis were shown to be robust for 
the majority of deterministic sensitivity analyses with one 
exception; using a cell salvage machine that required 
different consumables to those included in the main 
base case analyses, where the machine is only set up for 
processing in patients having blood returned and where 
Table 4 Results
Transfusion 
strategy
Average cost per 
patient (£)
Difference in 
costs (£)
Effectiveness
(donor blood 
transfusion avoided)
Incremental donor 
blood transfusion 
avoided
ICER per donor 
blood transfusion 
avoided (£)
Analysis ITT
Standard care 1244 0.965
Cell salvage 1327 83 0.975 0.010 8110
Analysis PP 
Standard care 1238 0.967
Cell salvage 1330 92 0.978 0.011 8252
Analysis ECS
Standard care 1352 0.986
Cell salvage 1407 55 0.990 0.004 13 713
ECS, emergency caesarean section; ICER, incremental cost-effectiveness ratio; ITT, intention to treat; PP, per protocol. 
Figure 2 Cost-effectiveness acceptability curve for donor 
blood transfusion avoided. ITT, intention to treat; PP, per 
protocol.
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swab washing is not conducted, resulted in a significant 
effect on the ICER, reducing it to £1022 per donor blood 
transfusion avoided.
A PP analysis produced an ICER of £8252 per transfu-
sion avoided, but this result should be considered with 
caution as the population in this analysis is a subset of 
the ITT population who completed the study without any 
major protocol violations.13 In clinical practice, uptake 
of cell salvage is unlikely to be ‘per-protocol’. In a third 
analysis, looking at emergency caesareans only, cell 
salvage appears to be more effective than standard care 
for avoiding a donor blood transfusion but the resulting 
ICER of £13 713 is driven by the increased probability that 
these patients will require a higher level of postoperative 
care and additional surgeries.
strengths and limitations of the study
The strength of this model-based economic evaluation is 
that it was based on a rigorously conducted RCT. The cost 
and outcome data measures that were incorporated into 
the model were collected prospectively during the RCT 
using forms filled out at the preoperative, intraoperative 
and postoperative phase and at the time of discharge from 
hospital. In addition, the economic evaluation benefited 
from significant clinical and statistical input throughout 
its design and development. All assumptions used in the 
model were agreed with the trial team before the anal-
ysis was carried out and without knowledge of how these 
assumptions would affect the results.
In terms of limitations, it was not possible to account 
for long-term implications relating to maternal fetal 
exposure as data relating to this were not available from 
the trial. In addition, information relating to the clinical 
status and care of the infant was not included in the anal-
ysis. A further limitation of the study is that outcomes 
were expressed in terms of clinical effectiveness rather 
than in terms of a standard unit of benefit such as the 
quality-adjusted life year. Finally, the use of platelets and 
other blood products has not been included in the study. 
However, the results of the sensitivity and threshold anal-
yses demonstrated that including these costs would not 
have impacted on the cost-effectiveness results.
strengths and weaknesses in relation to other studies
To date, there has only been one, small RCT looking 
at the elective use of cell salvage at caesarean section16 
and this study did not include an economic element. A 
Cochrane review of cell salvage in adult elective surgery 
assessed the clinical and cost-effectiveness of cell salvage 
and other autologous transfusion strategies in elective 
surgery.10 It suggested that cell salvage may be an ‘effec-
tive and cost-effective alternative to the allogeneic blood 
transfusion strategy’. However, no obstetric papers were 
identified for this review. A recent study by Lim et al17 
found the use of cell salvage for cases at high risk for 
obstetric haemorrhage to be economically reasonable 
while routine cell salvage use for all caesarean deliveries 
was not. In contrast to the current study, Lim et al adopted 
a societal perspective and used data from published 
research to populate the model.17
Meaning of the study
The results of the economic evaluation suggest that while 
routine cell salvage is a marginally more effective strategy 
than standard care in avoiding a donor blood transfusion, 
there is uncertainty in relation to whether it is a less or 
more costly strategy. Under the conditions reported here, 
for a high-income country such as the UK, where donor 
blood is typically available, cell salvage is unlikely to be 
considered a cost-effective alternative to the provision of 
donor blood by the health service. However, in lower/
middle-income countries where the provision of a safe 
and secure blood supply may be more challenging, the 
relative cost-effectiveness may be very different. In addi-
tion, the lack of long-term data on the health and quality 
of life of patients in both arms of the trial means that 
further research is needed to fully understand the cost 
implications of both strategies. For example, latent infec-
tion such as hepatitis may result in chronic liver disease 
within 20 or more years of incident of infection18 19 which 
has obvious long-term cost implications for the health-
care provider.
unanswered questions and future research
The current study has used data from a large, multicentre 
randomised trial which demonstrated modest evidence 
that routine use of cell salvage during caesarean section 
reduced the need for donor blood transfusion. The 
main cause of uncertainty relates to the long-term cost 
implications of adopting the routine use of cell salvage. 
Future studies should explore the long-term health and 
economic and quality of life impacts associated with both 
transfusion strategies. Also, evidence on the preferences 
of women needs to be considered. For example, hospi-
tals may wish to have the option of cell salvage available 
for Jehovah witness patients where there is no option to 
use donor blood. In countries where safe donor supply 
cannot be guaranteed the use of cell salvage might have 
very different implications which need to be explored.
Finally, the issue of donor blood as a scarce resource 
needs to be considered. As things currently stand, demand 
for donor blood is increasing, while on the other hand, 
enhanced safety measures are limiting the donor pool.20 21 
The impact of further restrictions on supply could create 
shortages under current usage patterns, and donor blood 
substitutes such as cell salvage play a potential role in 
helping to re-establish a demand–supply balance.22 23 Not 
considered in this study is the fact that transfusion with 
cell salvage can always exist. While there is an expecta-
tion that donor blood will always be there when needed, 
transfusion using donor blood simply cannot be guar-
anteed. In such a scenario, where the option of donor 
blood is limited or not available, the routine use of cell 
salvage would be dominant (less costly and more effec-
tive) compared with standard care, thus making provision 
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for the availability of the technology likely to be extremely 
important.
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